JPMorgan Chase & Co. Lowers Baxter International (NYSE:BAX) Price Target to $19.00

Baxter International (NYSE:BAX) had its price target reduced by investment analysts at JPMorgan Chase & Co. from $25.00 to $19.00 in a note issued to investors on Friday,MarketScreener reports. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 2.90% from the company’s current price.

Several other equities research analysts also recently weighed in on the company. Wall Street Zen downgraded Baxter International from a “buy” rating to a “hold” rating in a report on Saturday, August 2nd. Morgan Stanley decreased their price objective on Baxter International from $28.00 to $27.00 and set an “underweight” rating for the company in a report on Tuesday, July 15th. Barclays decreased their price objective on Baxter International from $41.00 to $36.00 and set an “overweight” rating for the company in a report on Monday, August 4th. Stifel Nicolaus reissued a “hold” rating and issued a $25.00 price objective (down from $36.00) on shares of Baxter International in a report on Monday, August 4th. Finally, Argus downgraded Baxter International from a “buy” rating to a “hold” rating in a report on Friday. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Baxter International has an average rating of “Hold” and an average price target of $23.70.

Baxter International Price Performance

BAX stock opened at $18.47 on Friday. The company has a market capitalization of $9.48 billion, a P/E ratio of -61.55, a PEG ratio of 0.73 and a beta of 0.58. Baxter International has a twelve month low of $18.42 and a twelve month high of $37.74. The business has a 50 day simple moving average of $23.14 and a 200-day simple moving average of $26.85. The company has a current ratio of 2.30, a quick ratio of 1.49 and a debt-to-equity ratio of 1.30.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Thursday, October 30th. The medical instruments supplier reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.60 by $0.09. The business had revenue of $2.84 billion during the quarter, compared to the consensus estimate of $2.88 billion. Baxter International had a positive return on equity of 16.96% and a negative net margin of 1.42%.The company’s revenue was up 5.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.80 earnings per share. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS. FY 2025 guidance at 2.350-2.400 EPS. As a group, equities analysts anticipate that Baxter International will post 2.48 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Raiffeisen Bank International AG increased its position in Baxter International by 24.9% during the 1st quarter. Raiffeisen Bank International AG now owns 95,668 shares of the medical instruments supplier’s stock worth $3,229,000 after purchasing an additional 19,081 shares in the last quarter. Dodge & Cox increased its position in Baxter International by 2.1% during the 1st quarter. Dodge & Cox now owns 51,458,925 shares of the medical instruments supplier’s stock worth $1,761,439,000 after purchasing an additional 1,081,631 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Baxter International by 30.9% in the 1st quarter. New York State Common Retirement Fund now owns 623,403 shares of the medical instruments supplier’s stock worth $21,339,000 after buying an additional 147,155 shares during the last quarter. Gabelli Funds LLC boosted its stake in Baxter International by 44.8% in the 1st quarter. Gabelli Funds LLC now owns 476,700 shares of the medical instruments supplier’s stock worth $16,317,000 after buying an additional 147,500 shares during the last quarter. Finally, ARGA Investment Management LP boosted its stake in Baxter International by 52.5% in the 1st quarter. ARGA Investment Management LP now owns 1,327,946 shares of the medical instruments supplier’s stock worth $45,456,000 after buying an additional 457,345 shares during the last quarter. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.